Oncothyreon Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oncothyreon

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Ian@SI who wrote (1989)	6/7/2004 3:34:34 PM
From: Jibacoa	Read Replies (1) of 2344

BIOM says the PIII of Theratope showed "statistically significant" results among women also taking hormonal therapy, but Merck KGa said it will return rights to Theratope back to Biomira because more trials of the vaccine are likely to be needed and the drug has missed Merck's timetable for a near-term product launch. (Women on hormonal therapy taking Theratope survived a median of 36.5 months vs. 30.7 months for controls.) The survival rate for women not receiving hormonal therapy showed no significant difference. The stock opened on a down gap, albeit it is up some from its earlier L.<g> bigcharts.marketwatch.com Bernard

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next